Skip to main content
Equibles
MBX logo

MBX · MBX Biosciences, Inc. · Metrics

Track MBX — free

Use MBX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MBX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$52.97 +2.68 (+5.33%) At close · Oct 27 Q2 2025 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$2.42B
Shares
48.16M
Volume · Oct 27 493.02K Avg daily vol (3M) 521.8K

MBX metrics

60 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$52.97
Market cap
$2.42B

Price action

20 metrics
Price change (1W)
-4.2%
Price change (30D)
-12.6%
Price change (3M)
-18.0%
Price change (6M)
+57.3%
Price change (YTD)
+59.4%
Price change (1Y)
+195.8%
Trailing year
Price change (5Y)
—
52-week high
$70.70
52-week low
$17.44
Change from 52-week high
-28.9%
Change from 52-week low
+188.4%
Annualized volatility
78.8%
Annualized volatility (3M)
52.2%
Beta
1.1
RSI (14D)
40.6
Price vs SMA 50
-14.6%
Price vs SMA 200
+11.2%
Avg volume (3M)
518,894
Relative volume
1.3
Average dollar volume
$31.00M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
48.16M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
5.7
reciprocal yield 17.5%
FCF yield
-3.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-30

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$117.92M
Net income (TTM)
−$104.32M
Trailing 12 months
Diluted EPS (TTM)
$-2.37
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$8.22

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+42.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-25.5%
Return on assets
-23.9%
Debt / equity
0.0
Current ratio
18.1
EBITDA (TTM)
—
Free cash flow (TTM)
−$85.20M
Quick ratio
18.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$418.58M
Latest balance sheet
Cash & equivalents
$54.12M
Total assets
$435.91M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$82.67M
Capital expenditures (TTM)
$2.53M
R&D (TTM)
$88.49M
SG&A (TTM)
—
Stock compensation (TTM)
$16.45M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
175
13F filer change QoQ
+17
Institutional ownership
116.4%
Conviction holders (share of 13F filers)
4.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.4%
Holder tenure
6.4
Price vs estimated holder cost
+97.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.7%

Short interest

3 metrics
Short interest
9.2%
Latest settlement · 7.5 days to cover
Days to cover
7.5d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$24,335
Insider-sentiment score
57 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1776111 CUSIP 55287L101 13F (30d) 21 filings 21 filers Visit website Investor relations